AstraZeneca Group (AZN)
AstraZeneca Group Free Cash Flow TTM: 6.874B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AZN Free Cash Flow TTM Rankings
| Overall | 98th percentile | 50 of 4138 |
| Sector | 98th percentile | 8 of 480 in Healthcare |
| Industry | 72nd percentile | 7 of 25 in Drug Manufacturers - Major |
AZN Free Cash Flow TTM Range, Past 5 Years
| Minimum | 1.946B | Sep 2007 |
| Maximum | 11.66B | Sep 2008 |
| Average | 8.314B |
About Free Cash Flow (TTM)
Free Cash Flow (TTM) is the sum of the last four quarters of Free Cash Flows.
For details about how YCharts calculates its quarterly Free Cash Flow numbers, click "Learn More" below.
Learn More
You may also be interested in these AZN related companies
AZN News
$AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies)
about 4 days ago by WallStreetBean
about 4 days ago by WallStreetBean
RT @SeemaCnbc Cancer data expected to move big pharma $JNJ $PFE $AZN
about 10 days ago by StockTwits
about 10 days ago by StockTwits
$AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ
about 14 days ago by WallStreetBean
about 14 days ago by WallStreetBean
AstraZeneca (AZN) Says SYMBICORT Shows Similar Safety Profile to Budesonide in Certain Asthma Patient Groups
May 10, 9:02AM Street Insider
May 10, 9:02AM Street Insider
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
May 08, 9:14AM Street Insider
May 08, 9:14AM Street Insider
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 20 days ago by abubnic
about 20 days ago by abubnic
$AMRN U.K.'s second-biggest drugmaker, pharmaceutical giant $AZN, based in London is sniffing around Ireland's small biotech $AMRN
about 23 days ago by JasonMilano8
about 23 days ago by JasonMilano8
News related to $AZN, currently +0.3% since open: 'Impax Labs falls on weak sales, new FDA warning' http://stks.co/3bhx
about 26 days ago by TradeBot
about 26 days ago by TradeBot
what kinda drug is that? RT @JNapodano $AZN reported $16M in sales of Vimovo - not great, but still higher than consensus. $POZN.
about 27 days ago by WallStreetBean
about 27 days ago by WallStreetBean
Morning News: April 26, 2012 | via @EddyElfenbein http://stks.co/3Wht $FED $DB $NDX $AAPL $CAT $AZN
about 31 days ago by STNet
about 31 days ago by STNet
$AZN trouble in paradise: AstraZeneca CEO to step down as Q1 profit plunges http://stks.co/3WZ3 (holding)
about 31 days ago by WallStreetBean
about 31 days ago by WallStreetBean
News related to $AZN: 'AstraZeneca CEO to step down as Q1 profit plunges' http://stks.co/3WIC
about 32 days ago by TradeBot
about 32 days ago by TradeBot
@taketheplunge $AMRN $AZN has been linked to every biotech on the market in the last 3 months. $AZN could buy...
about 32 days ago by jackofalltrade
about 32 days ago by jackofalltrade
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.23 | +0.05 | +0.12% | 53.28B |
| AZK | 4.72 | +0.11 | +2.39% | 769.97M |
| AZC | 1.63 | +0.13 | +8.67% | 235.05M |
| AYR | 11.60 | +0.37 | +3.29% | 839.61M |
| BCRX | 3.26 | +0.00 | +0.00% | 150.09M |
| BCR | 99.90 | -0.09 | -0.09% | 8.473B |
| BCPC | 30.31 | -0.25 | -0.82% | 885.36M |
| BCOM | 4.20 | +0.01 | +0.24% | 125.54M |
| BCO | 23.23 | -0.32 | -1.36% | 1.089B |
| BCH | 84.05 | +0.83 | +1.00% | 12.18B |
